Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 May;36(5):771–777. doi: 10.1136/gut.36.5.771

Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.

H Friess 1, J Langhans 1, M Ebert 1, H G Beger 1, J Stollfuss 1, S N Reske 1, M W Büchler 1
PMCID: PMC1382685  PMID: 7797130

Abstract

The detection of pancreatic cancer or the discrimination between pancreatic cancer and chronic pancreatitis remains an important diagnostic problem. The increased glucose metabolism in malignant tumours formed the basis for this investigation, which focused on the role of positron emission tomography (PET) with 2[18F]-fluoro-2-deoxy-D-glucose (FDG) in the detection of pancreatic cancer and its differentiation from chronic pancreatitis. Eighty patients admitted for elective pancreatic surgery received preoperatively 250-350 mBq FDG intravenously and emission scans were recorded 45 minutes later. Intense focal activity in the pancreatic region was taken at the time of scanning as showing the presence of pancreatic cancer. The presence of cancer was later confirmed by histological examination of the surgical specimens and histological findings were compared with the preoperative PET results. Forty one patients with pancreatic cancer (group I: n = 42) had a focally increased FDG uptake in the pancreatic region. Two patients with a periampullary carcinoma (group II: n = 6) failed to develop FDG accumulation. In 28 patients with chronic pancreatitis (group III: n = 32) no FDG accumulation occurred. Overall sensitivity and specificity of PET for malignancy (group I + II) were 94% (45 of 48) and 88% (28 of 32), respectively. The standard uptake value of the patients with pancreatic carcinoma was significantly higher than in patients with chronic pancreatitis (3.09 (2.18) v 0.87 (0.56); p < 0.001; median (interquartile range)). These findings show that FDG-PET represents a new and non-invasive diagnostic procedure for the diagnosis of pancreatic cancer and to differentiate pancreatic cancer from chronic pancreatitis. However, the diagnostic potential of this technique requires further evaluation.

Full text

PDF
771

Images in this article

774Figure 2
on p.774
775Figure 3
on p.775

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell J. P., Wilson S. R. Pancreatic neoplasms: how useful is evaluation with US? Radiology. 1988 May;167(2):341–344. doi: 10.1148/radiology.167.2.3282254. [DOI] [PubMed] [Google Scholar]
  2. Di Chiro G., Hatazawa J., Katz D. A., Rizzoli H. V., De Michele D. J. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987 Aug;164(2):521–526. doi: 10.1148/radiology.164.2.3496626. [DOI] [PubMed] [Google Scholar]
  3. Freeny P. C., Ball T. J. Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) in the evaluation of suspected pancreatic carcinoma: diagnostic limitations and contemporary roles. Cancer. 1981 Mar 15;47(6 Suppl):1666–1678. doi: 10.1002/1097-0142(19810315)47:6+<1666::aid-cncr2820471435>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  4. Gallagher B. M., Fowler J. S., Gutterson N. I., MacGregor R. R., Wan C. N., Wolf A. P. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978 Oct;19(10):1154–1161. [PubMed] [Google Scholar]
  5. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer. 1987 Nov 1;60(9):2284–2303. doi: 10.1002/1097-0142(19871101)60:9<2284::aid-cncr2820600930>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  6. Hamacher K., Coenen H. H., Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986 Feb;27(2):235–238. [PubMed] [Google Scholar]
  7. Klever P., Bares R., Fass J., Büll U., Schumpelick V. PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet. 1992 Nov 7;340(8828):1158–1159. doi: 10.1016/0140-6736(92)93183-n. [DOI] [PubMed] [Google Scholar]
  8. Langen K. J., Braun U., Rota Kops E., Herzog H., Kuwert T., Nebeling B., Feinendegen L. E. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993 Mar;34(3):355–359. [PubMed] [Google Scholar]
  9. Okada J., Yoshikawa K., Itami M., Imaseki K., Uno K., Itami J., Kuyama J., Mikata A., Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992 Mar;33(3):325–329. [PubMed] [Google Scholar]
  10. Persons D. A., Schek N., Hall B. L., Finn O. J. Increased expression of glycolysis-associated genes in oncogene-transformed and growth-accelerated states. Mol Carcinog. 1989;2(2):88–94. doi: 10.1002/mc.2940020207. [DOI] [PubMed] [Google Scholar]
  11. Poston G. J., Gillespie J., Guillou P. J. Biology of pancreatic cancer. Gut. 1991 Jul;32(7):800–812. doi: 10.1136/gut.32.7.800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Raptopoulos V., Schellinger D. Imaging of the pancreas with computed tomography. Comput Tomogr. 1979;3(1):37–47. doi: 10.1016/0363-8235(75)90007-1. [DOI] [PubMed] [Google Scholar]
  13. Schek N., Hall B. L., Finn O. J. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res. 1988 Nov 15;48(22):6354–6359. [PubMed] [Google Scholar]
  14. Strauss L. G., Conti P. S. The applications of PET in clinical oncology. J Nucl Med. 1991 Apr;32(4):623–650. [PubMed] [Google Scholar]
  15. Syrota A., Duquesnoy N., Paraf A., Kellershohn C. The role of positron emission tomography in the detection of pancreatic disease. Radiology. 1982 Apr;143(1):249–253. doi: 10.1148/radiology.143.1.6977792. [DOI] [PubMed] [Google Scholar]
  16. WARBURG O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309–314. doi: 10.1126/science.123.3191.309. [DOI] [PubMed] [Google Scholar]
  17. Wahl R. L., Cody R. L., Hutchins G. D., Mudgett E. E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991 Jun;179(3):765–770. doi: 10.1148/radiology.179.3.2027989. [DOI] [PubMed] [Google Scholar]
  18. Warshaw A. L., Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992 Feb 13;326(7):455–465. doi: 10.1056/NEJM199202133260706. [DOI] [PubMed] [Google Scholar]
  19. Yonekura Y., Benua R. S., Brill A. B., Som P., Yeh S. D., Kemeny N. E., Fowler J. S., MacGregor R. R., Stamm R., Christman D. R. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982 Dec;23(12):1133–1137. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES